Literature DB >> 24163092

Recurrent varicella following steroids and fingolimod in a Multiple Sclerosis patient.

D Ferraro1, S De Biasi, F Vitetta, A M Simone, L Federzoni, V Borghi, A Cossarizza, P F Nichelli, P Sola.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24163092     DOI： 10.1007/s11481-013-9510-4

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN： 1557-1890            Impact factor:   4.147


× No keyword cloud information.
  10 in total

Review 1.  Natural regulatory T cells and persistent viral infection.

Authors:  Shuo Li; Eric J Gowans; Claire Chougnet; Magdalena Plebanski; Ulf Dittmer
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

2.  Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod.

Authors:  John N Ratchford; Kathleen Costello; Daniel S Reich; Peter A Calabresi
Journal:  Neurology       Date:  2012-10-03       Impact factor: 9.910

3.  Methylprednisolone treatment increases the proportion of the highly suppressive HLA-DR(+)-Treg-cells in transplanted patients.

Authors:  Nicole Seissler; Edgar Schmitt; Friederike Hug; Claudia Sommerer; Martin Zeier; Matthias Schaier; Andrea Steinborn
Journal:  Transpl Immunol       Date:  2012-09-26       Impact factor: 1.708

4.  Recent steroid therapy increases severity of varicella infections in children with acute lymphoblastic leukemia.

Authors:  Garick Hill; Allen R Chauvenet; James Lovato; Thomas W McLean
Journal:  Pediatrics       Date:  2005-10       Impact factor: 7.124

5.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Authors:  Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Bhupendra O Khatri; Xavier Montalban; Jean Pelletier; Ruggero Capra; Paolo Gallo; Guillermo Izquierdo; Klaus Tiel-Wilck; Ana de Vera; James Jin; Tracy Stites; Stacy Wu; Shreeram Aradhye; Ludwig Kappos
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

6.  T-cell response against varicella-zoster virus in fingolimod-treated MS patients.

Authors:  Meret E Ricklin; Johannes Lorscheider; Anne Waschbisch; Cecile Paroz; Satish K Mehta; Duane L Pierson; Jens Kuhle; Bettina Fischer-Barnicol; Till Sprenger; Raija L P Lindberg; Ludwig Kappos; Tobias Derfuss
Journal:  Neurology       Date:  2013-05-22       Impact factor: 9.910

7.  A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination.

Authors:  Thomas Verstraeten; Aisha O Jumaan; John P Mullooly; Jane F Seward; Hector S Izurieta; Frank DeStefano; Steven B Black; Robert T Chen
Journal:  Pediatrics       Date:  2003-08       Impact factor: 7.124

8.  Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens.

Authors:  Einar M Aandahl; Jakob Michaëlsson; Walter J Moretto; Frederick M Hecht; Douglas F Nixon
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

9.  CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses.

Authors:  Susmit Suvas; Uday Kumaraguru; Christopher D Pack; Sujin Lee; Barry T Rouse
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307

10.  Fingolimod modulates peripheral effector and regulatory T cells in MS patients.

Authors:  Laura D Serpero; Gilberto Filaci; Alessia Parodi; Florinda Battaglia; Francesca Kalli; Davide Brogi; Giovanni Luigi Mancardi; Antonio Uccelli; Daniela Fenoglio
Journal:  J Neuroimmune Pharmacol       Date:  2013-05-07       Impact factor: 4.147
  10 in total
  3 in total

Review 1.  Infection risk in patients on multiple sclerosis therapeutics.

Authors:  Eric M Williamson; Joseph R Berger
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

2.  Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.

Authors:  Andrea Harrer; Peter Wipfler; Georg Pilz; Katrin Oppermann; Elisabeth Haschke-Becher; Shahrzad Afazel; Jörg Kraus; Eugen Trinka; Johann Sellner
Journal:  Int J Mol Sci       Date:  2015-09-10       Impact factor: 5.923

3.  Modulation of Tregs and iNKT by Fingolimod in Multiple Sclerosis Patients.

Authors:  Diana Ferraro; Sara De Biasi; Anna Maria Simone; Riccardo Orlandi; Milena Nasi; Francesca Vitetta; Marcello Pinti; Marco Fogliani; Stefano Meletti; Andrea Cossarizza; Patrizia Sola
Journal:  Cells       Date:  2021-11-26       Impact factor: 6.600
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.